Checkpoint Therapeutics I... (CKPT)
| Bid | 2.53 |
| Market Cap | 123.22M |
| Revenue (ttm) | 52.42K |
| Net Income (ttm) | -51.83M |
| EPS (ttm) | -1.83 |
| PE Ratio (ttm) | -1.4 |
| Forward PE | 10.7 |
| Analyst | Buy |
| Ask | 2.56 |
| Volume | 936,808 |
| Avg. Volume (20D) | 1,318,956 |
| Open | 2.86 |
| Previous Close | 2.86 |
| Day's Range | 2.54 - 2.84 |
| 52-Week Range | 1.38 - 4.50 |
| Beta | 1.36 |
About CKPT
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-...
Analyst Forecast
According to 3 analyst ratings, the average rating for CKPT stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 251.56% from the latest price.
2 months ago · seekingalpha.com
Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's ApprovalCheckpoint Therapeutics, Inc. received FDA approval for Unloxcyt, the first PD-L1 drug for advanced cSCC, with strong clinical results and a market-disruptive pricing strategy. Despite mixed investor ...